Clinical Trial Update: Dara-BCD for Rare MGRS [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on the Dara-BCD regimen (daratumumab with bortezomib, cyclophosphamide, and dexamethasone) for Monoclonal Gammopathy of Renal Sign…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monoclonal Gammopathy of Renal Significance

Drugs mentioned

• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Monoclonal Gammopathy of Renal Significance (MGRS) | Phase 2 | Status: NOT_YET_RECRUITING